Acelyrin, Inc. (NasdaqGM: SLRN)
Health Care · Biotechnology · US
$—
— today · — 1Y
Acelyrin, Inc. (NasdaqGM: SLRN) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Acelyrin, Inc. across four factors: quality 49/100, value 58/100. Its strongest factor is value.
SLRN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.69
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 83
- Next earnings
- —
About Acelyrin, Inc.
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
- ISIN
- US00445A1007
- Founded
- 2020
- Listed since
- May 4, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.